184368-74-9

Usage

Uses

Used in Pharmaceutical Industry:
4(2H)-Pyridinedicarboxylic acid, 3,6-dihydro-, 1-(1,1-dimethylethyl)4-methyl ester is used as an intermediate in the synthesis of various pharmaceuticals, particularly angiotensin receptor antagonists. Its role in the development of these medications is crucial due to its ability to contribute to the formation of the active compounds that help in managing hypertension and heart failure.
Used in Organic Chemical Manufacturing:
In the manufacturing of other organic chemicals, 4(2H)-Pyridinedicarboxylic acid, 3,6-dihydro-, 1-(1,1-dimethylethyl)4-methyl ester serves as a key intermediate. Its presence in the synthesis process allows for the creation of a wide range of organic compounds that can be utilized in various industries, showcasing its importance as a building block in chemical production.
Used in Drug Development:
As a versatile chemical, 4(2H)-Pyridinedicarboxylic acid, 3,6-dihydro-, 1-(1,1-dimethylethyl)4-methyl ester is also used in drug development. Its ability to participate in numerous chemical reactions and functional groups makes it a valuable component in the creation of new and innovative pharmaceuticals, contributing to advancements in medical treatments and therapies.

Upstream product

• 67-56-1 methanol 
• 201230-82-2 carbon monoxide 
• 138647-49-1 4-Trifluoromethanesulfonyloxy-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 70684-84-3 1-[(tert-butoxy)carbonyl]-1,2,3,6-tetrahydropyridine-4-carboxylic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 24424-99-5 di-tert-butyl dicarbonate 
• 792136-23-3 methyl 1,2,3,6-tetrahydro-4-pyridinecarboxylate 
• 80845-58-5 methyl 1-benzyl-1,2,3,6-tetrahydropyridine-4-carboxylate 
• 94983-57-0 1-benzyl-4-(methoxycarbonyl)pyridin-1-ium 
• 2459-09-8 4-pyridinecarboxylic acid, methyl ester 
• 50893-53-3 carbonochloridic acid 1-chloro-ethyl ester 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 

Downstream Products

• 203663-26-7 t-butyl 4-(hydroxymethyl)-3,6-dihydropyridine-1(2H)-carboxylate 
• 906663-27-2 3-benzylsulfanyl-4-[1-(1-benzylsulfanylmethyl-4-butylcarbamoyl-2-hydroxypentylcarbamoyl)ethylcarbamoyl]piperidine-1-carboxylic acid tert-butyl ester 
• 906663-26-1 (3R,4S)-3-benzylsulfanylpiperidine-1,4-dicarboxylic acid 1-tert-butyl ester 

Relevant academic research and scientific papers

Palladium-Catalyzed Visible-Light-Driven Carboxylation of Aryl and Alkenyl Triflates by Using Photoredox Catalysts

A visible-light-driven carboxylation of aryl and alkenyl triflates with CO2 is developed by using a combination of Pd and photoredox catalysts. This reaction proceeds under mild conditions and can be applied to a wide range of substrates including acyclic alkenyl triflates.

PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS

Compounds of formula (I) wherein R1, R2,R3,R4,R5,R23,R24,L, A and Bare as defined in claim 1, or pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as cytochrome P450 monooxygenase 11A1(CYP11A1) inhibitors. The compounds are useful as medicaments in the treatment of steroidreceptor, particularly androgen receptor,dependent diseases and conditions, such asprostate cancer.

Novel Compounds as Autotaxin Inhibitors and Pharmaceutical Compositions Comprising the Same

The present invention relates to a novel autotaxin inhibitor compound for preventing and treating disease or symptoms due to an increase in concentration of lysophosphatidic acid or activation of autotaxin. The present invention further relates to a pharmaceutical composition containing the same. The novel compound of the present invention is an autotaxin inhibitor which inhibits production of lysophosphatidic acid, and thus is useful for treating or preventing cardiovascular disease, cancer, metabolic disease, kidney disease, liver disease, inflammatory diseases, nervous disease, respiratory disease, desmoid disease, eye disease, cholestatic symptoms, other types of chronic pruritus or acute, or chronic rejection of transplanted organs.COPYRIGHT KIPO 2017

Structure-based design and synthesis of macroheterocyclic peptidomimetic inhibitors of the aspartic protease β-site amyloid precursor protein cleaving enzyme (BACE)

Based on the X-ray cocrystal structure of the Tang-Ghosh heptapeptide inhibitor 1 (OM00-3), a series of macroheterocyclic analogues were designed and synthesized. Analogues containing dithia, dioxa, oxathia, and carbathia macrocycles were synthesized by m

Benzopiperidine derivatives

Benzopiperidine derivatives represented by formula (I), salts thereof or hydrates thereof, processes for producing the same and drugs comprising the same: wherein the variables are as described in the specification. These compounds are useful as drugs efficacious in the prevention and treatment of these various inflammatory diseases and immunologic diseases, such as rheumatoid arthritis, atopic dermatitis, psoriasis, asthma, and rejection reaction accompanying organ transplantation.

AROMATIC AMIDES

This application relates to a compound of formula I (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.

Synthesis of 2-or/and 6-methylated analogues of isoguvacine (1,2,3,6-tetrahydropyridine-4-carboxylic acid) a GABAA agonist

1,2,3,6-Tetrahydropyridine-4-carboxylic acid (isoguvacine) and related 2-and/or 6-methylated analogues (1-4) were synthesized using the methoxycarbonylation [Pd(OAc)2, PPh3, CO, MeOH)] of their corresponding vinylic triflates. Analogue (5), the 6-methyl-1,2,3,6-tetrahydropyridine-4-carboxylic acid was obtained after a reductive deoxygenation of the corresponding β-keto ester.